Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: Pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline

World Journal of Biological Psychiatry

Volumn 15, Issue 2, 2014, Pages 155-166

  Bandelow, Borwin ^a   Bauer, Michael ^b   Vieta, Eduard ^c   El Khalili, Nizar ^d   Gustafsson, Urban ^e   Earley, Willie R ^f   Eriksson, Hans ^e  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Alpine Clinic   (United States)

^e ASTRAZENECA R AND D   (Sweden)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Adjunct therapy; Anxious depression; Atypical antipsychotic; Extended release quetiapine fumarate; Major depressive disorder

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; QUETIAPINE; DELAYED RELEASE FORMULATION; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; EXTENDED RELEASE PREPARATION; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; PITTSBURGH SLEEP QUALITY INDEX; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SOMATIZATION; SYMPTOM; TABLET FORMULATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; COMORBIDITY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84893862796     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2013.842654     Document Type: Article

References (70)

1. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association.
2. American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association. AstraZeneca.
3. Seroquel XR (quetiapine fumarate) extendedrelease tablets-US prescribing information [Internet]. 25 October 2012. Available from: http://www1. astrazeneca-us. com/pi/seroquelxr.pdf. AstraZeneca UK Limited.
4. Seroquel XL Summary of Product Characteristics (UK) [Internet]. 26 April 2012. Available from: http://www.medicines.org.uk/EMC/medicine/21175/SPC/.
5. Baghai TC , Blier P , Baldwin DS , Bauer M , Goodwin GM , Fountoulakis KN , et al. 2011. General and comparative effi cacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 261(Suppl 3) : 207-245.
6. Baldwin DS , Huusom AK , Maehlum E. 2006. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 189 : 264-272. (Pubitemid 44343473)
7. Ballenger JC. 1999. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 60(Suppl 22) : 29-34. (Pubitemid 30107953)
8. Bandelow B. 2003. Epidemiology of depression and anxiety. In: Kasper S , den Boer JA , Sitsen AJM , editors. Handbook on depression and anxiety. New York, NY: Marcel Dekker. p 49-68.
9. Bandelow B , Andersen HF , Dolberg OT. 2007. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety 24 : 53-61. (Pubitemid 46278680)
10. Bandelow B , Chouinard G , Bobes J , Ahokas A , Eggens I , Liu S , et al. 2010. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placeboand active-controlled study. Int J Neuropsychopharmacol 13 : 305-320.
11. Bauer M , El-Khalili N , Datto C , Szamosi J , Eriksson H. 2010. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 127 : 19-30.
12. Bauer M , Pretorius HW , Constant EL , Earley WR , Szamosi J , Brecher M. 2009. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70 : 540-549.
13. Belzer K , Schneier FR. 2004. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract 10 : 296-306. (Pubitemid 39299042)
14. Bortnick B , El-Khalili N , Banov M , Adson D , Datto C , Raines S , et al. 2011. Effi cacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 128 : 83-94.
15. Boulenger JP , Hermes A , Huusom AK , Weiller E. 2010. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. Curr Med Res Opin 26 : 605-614.
16. Boylan KR , Bieling PJ , Marriott M , Begin H , Young LT , MacQueen GM. 2004. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 65 : 1106-1113.
17. Brown C , Schulberg HC , Madonia MJ , Shear MK , Houck PR. 1996. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 153 : 1293-1300. (Pubitemid 26334202)
18. Buysse DJ , Reynolds CF , III , Monk TH , Berman SR , Kupfer DJ. 1989. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28 : 193-213. (Pubitemid 19144991)
19. Chouinard G. 2004. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 65(Suppl 5) : 7-12.
20. Cleary P , Guy W. 1977. Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1 : 115-120.
21. Cutler AJ , Montgomery SA , Feifel D , Lazarus A , Å str ö m M , Brecher M. 2009. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry 70 : 526-539.
22. Davidson JR , Meoni P , Haudiquet V , Cantillon M , Hackett D. 2002. Achieving remission with venlafaxine and fl uoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety 16 : 4-13. (Pubitemid 34977120)
23. De Nayer A , Geerts S , Ruelens L , Schittecatte M , De Bleeker E , Van Eeckhoutte I , et al. 2002. Venlafaxine compared with fl uoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 5 : 115-120. (Pubitemid 34662973)
24. Dombrovski AY , Mulsant BH , Houck PR , Mazumdar S , Lenze EJ , Andreescu C , et al. 2007. Residual symptoms and recurrence during maintenance treatment of late-life depression . J Affect Disord 103 : 77-82. (Pubitemid 47445755)
25. Dunner DL , Goldstein DJ , Mallinckrodt C , Lu Y , Detke MJ. 2003. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 18 : 53-61. (Pubitemid 37175581)
26. Duru G , Fantino B. 2008. The clinical relevance of changes in the Montgomery-Å sberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin 24 : 1329-1335. (Pubitemid 351741564)
27. El-Khalili N , Joyce M , Atkinson S , Buynak RJ , Datto C , Lindgren P , et al. 2010. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13 : 917-932.
28. Fava M , Rosenbaum JF , Hoog SL , Tepner RG , Kopp JB , Nilsson ME. 2000. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and effi cacy in anxious depression . J Affect Disord 59 : 119-126. (Pubitemid 30317428)
29. Fava M , Rush AJ , Alpert JE , Balasubramani GK , Wisniewski SR , Carmin CN , et al. 2008. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR * D report. Am J Psychiatry 165 : 342-351. (Pubitemid 351704490)
30. Fava M , Schaefer K , Huang H , Wilson A , Iosifescu DV , Mischoulon D , et al. 2011. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry 72 : 473-479.
31. Fawcett J , Scheftner WA , Fogg L , Clark DC , Young MA , Hedeker D , et al. 1990. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 147 : 1189-1194. (Pubitemid 20275373)
32. Flint AJ , Rifat SL. 1997. Two-year outcome of elderly patients with anxious depression. Psychiatry Res 66 : 23-31. (Pubitemid 27111377)
33. Gonzalez-Pinto A , Galan J , Martin-Carrasco M , Ballesteros J , Maurino J , Vieta E. 2012. Anxiety as a marker of severity in acute mania. Acta Psychiatr Scand 126 : 351-355.
34. Guy W. 1976. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare. p. 218-222.
35. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32 : 50-55.
36. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 : 56-62.
37. Hirschfeld RM , Weisler RH , Raines SR , Macfadden W. 2006. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67 : 355-362.
38. Joffe RT , Bagby RM , Levitt A. 1993. Anxious and nonanxious depression. Am J Psychiatry 150 : 1257-1258. (Pubitemid 23218913)
39. Katila H , Mezhebovsky I , Mulroy A , Berggren L , Eriksson H , Earley W , et al. 2013. Randomized, double-blind study of the effi cacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry 21 : 769-784.
40. Kauer-Sant ' Anna M , Kapczinski F , Vieta E. 2009. Epidemiology and management of anxiety in patients with bipolar disorder. CNS Drugs 23 : 953-964.
41. Kessler RC , Nelson CB , McGonagle KA , Liu J , Swartz M , Blazer DG. 1996. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl 168 : 17-30. (Pubitemid 26000488)
42. Khan A , Joyce M , Atkinson S , Eggens I , Baldytcheva I , Eriksson H. 2011. A randomized, double-blind study of oncedaily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 31 : 418-428.
43. Kurian BT , Greer TL , Trivedi MH. 2009. Strategies to enhance the therapeutic effi cacy of antidepressants: targeting residual symptoms. Expert Rev Neurother 9 : 975-984.
44. Lepola U , Arato M , Zhu Y , Austin C. 2003. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 64 : 654-662. (Pubitemid 36750142)
45. McIntyre RS , Konarski JZ , Soczynska JK , Kennedy SH. 2007. Residual anxiety symptoms in depressed primary care patients. J Psychiatr Pract 13 : 125-128. (Pubitemid 46588317)
46. Merideth C , Cutler A , She F , Eriksson H. 2012. Effi cacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the acute treatment of generalized anxiety disorder (GAD): a randomized, placebo-and active-controlled study. Int Clin Psychopharmacol 27 : 40-54.
47. Mezhebovsky I , Mägi K , She F , Datto C , Eriksson H. 2013. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry 28 : 615-625.
48. Montgomery SA , Å sberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134 : 382-389. (Pubitemid 9136500)
49. Murphy JM , Horton NJ , Laird NM , Monson RR , Sobol AM , Leighton AH. 2004. Anxiety and depression: a 40-year perspective on relationships regarding prevalence, distribution, and comorbidity. Acta Psychiatr Scand 109 : 355-375. (Pubitemid 38491282)
50. Nelson JC. 2010. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress Anxiety 27 : 12-18.
51. Office of Applied Studies. Suicidal Thoughts, Suicide Attempts, Major Depressive Episode, and Substance Use among Adults [Internet] 2006. Available from: http://www.oas.samhsa. gov/2k6/suicide/suicide.pdf.
52. Papakostas GI , Clain A , Ameral VE , Baer L , Brintz C , Smith WT , et al. 2010. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol 25 : 17-21.
53. Papakostas GI , Fan H , Tedeschini E. 2012. Severe and anxious depression: combining defi nitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 22 : 347-355.
54. Papakostas GI , Larsen K. 2011. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Eur Arch Psychiatry Clin Neurosci 261 : 147-156.
55. Papakostas GI , Stahl SM , Krishen A , Seifert CA , Tucker VL , Goodale EP , et al. 2008. Effi cacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 69 : 1287-1292.
56. Ramana R , Paykel ES , Cooper Z , Hayhurst H , Saxty M , Surtees PG. 1995. Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med 25 : 1161-1170.
57. Ravindran AV , Judge R , Hunter BN , Bray J , Morton NH. 1997. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 58 : 112-118. (Pubitemid 27149252)
58. Rickels K , Pollack MH , Feltner DE , Lydiard RB , Zimbroff DL , Bielski RJ , et al. 2005. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebocontrolled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62 : 1022-1030. (Pubitemid 41248382)
59. Roy-Byrne PP , Stang P , Wittchen HU , Ustun B , Walters EE , Kessler RC. 2000. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry 176 : 229-235. (Pubitemid 30179841)
60. Russell JM , Koran LM , Rush J , Hirschfeld RM , Harrison W , Friedman ES , et al. 2001. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 13 : 18-27. (Pubitemid 32537090)
61. Silverstone PH , Salinas E. 2001. Effi cacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 62 : 523-529. (Pubitemid 32703091)
62. Thase ME , Demyttenaere K , Earley W , Gustafsson U , Udd M , Eriksson H. 2012. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety 29 : 574-586.
63. Tollefson GD , Holman SL , Sayler ME , Potvin JH. 1994. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 55 : 50-59. (Pubitemid 24081821)
64. Trivedi MH , Thase ME , Fava M , Nelson CJ , Yang H , Qi Y , et al. 2008. Adjunctive aripiprazole in major depressive disorder: analysis of effi cacy and safety in patients with anxious and atypical features. J Clin Psychiatry 69 : 1928-1936.
65. Uhlenhuth EH , Balter MB , Ban TA , Yang K. 1999. Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997. Eur Neuropsychopharmacol 9(Suppl 6) : S393-398.
66. VanValkenburg C , Akiskal HS , Puzantian V , Rosenthal T. 1984. Anxious depressions. Clinical, family history, and naturalistic outcome-comparisons with panic and major depressive disorders . J Affect Disord 6 : 67-82. (Pubitemid 14158974)
67. Vieta E , Colom F. 2011. Therapeutic options in treatmentresistant depression. Ann Med 43 : 512-530.
68. Weisler R , Joyce M , McGill L , Lazarus A , Szamosi J , Eriksson H. 2009. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 14 : 299-313.
69. Wiethoff K , Bauer M , Baghai TC , Möller HJ , Fisher R , Hollinde D , et al. 2010. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German algorithm project. J Clin Psychiatry 71 : 1047-1054.
70. Wittchen HU , Zhao S , Kessler RC , Eaton WW. 1994. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51 : 355-364. (Pubitemid 24176813)